Trial Profile
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 12 Apr 2024 Planned End Date changed from 1 Dec 2028 to 1 Dec 2026.
- 12 Apr 2024 Planned primary completion date changed from 1 Apr 2028 to 1 Apr 2026.
- 28 Aug 2020 Status changed from recruiting to active, no longer recruiting.